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RESEARCH ARTICLE
Consensus Statement on Ethical & Safety Practices for
Conducting Digital Monitoring Studies with People at
Risk of Suicide and Related Behaviors
Matthew K. Nock, Ph.D., Evan M. Kleiman, Ph.D., Melissa Abraham, Ph.D., Kate H. Bentley, Ph.D., David A. Brent, M.D.,
Ralph J. Buonopane, Ph.D., Franckie Castro‐Ramirez, A.M., Christine B. Cha, Ph.D., Walter Dempsey, Ph.D.,
John Draper, Ph.D., Catherine R. Glenn, Ph.D., Jill Harkavy‐Friedman, Ph.D., Michael R. Hollander, Ph.D.,
Jeffrey C. Huffman, M.D., Hye In S. Lee, B.S., Alexander J. Millner, Ph.D., David Mou, M.D., Jukka‐Pekka Onnela, Ph.D.,
Rosalind W. Picard, Ph.D., Heather M. Quay, J.D., Osiris Rankin, A.M., Shannon Sewards, M.A., John Torous, M.D.,
Joan Wheelis, M.D., Ursula Whiteside, Ph.D., Galia Siegel, Ph.D., Anna E. Ordóñez, M.D., Jane L. Pearson, Ph.D.
Objective: Digital monitoring technologies (e.g., smart-
phones and wearable devices) provide unprecedented
opportunities to study potentially harmful behaviors such
as suicide, violence, and alcohol/substance use in real‐
time. The use of these new technologies has the potential
to significantly advance the understanding, prediction, and
prevention of these behaviors. However, such technolo-
gies also introduce myriad ethical and safety concerns,
such as deciding when and how to intervene if a partici-
pant's responses indicate elevated risk during the study?
Methods:We used a modified Delphi process to develop a
consensus among a diverse panel of experts on the ethical
and safety practices for conducting digital monitoring
studies with those at risk for suicide and related behaviors.
Twenty‐four experts including scientists, clinicians, ethi-
cists, legal experts, and those with lived experience pro-
vided input into an iterative, multi‐stage survey, and
discussion process.
Results: Consensus was reached on multiple aspects of
such studies, including: inclusion criteria, informed con-
sent elements, technical and safety procedures, data re-
view practices during the study, responding to various
levels of participant risk in real‐time, and data and safety
monitoring.
Conclusions: This consensus statement provides guidance
for researchers, funding agencies, and institutional review
boards regarding expert views on current best practices for
conducting digital monitoring studies with those at risk for
suicide—with relevance to the study of a range of other
potentially harmful behaviors (e.g., alcohol/substance use
and violence). This statement also highlights areas in which
more data are needed before consensus can be reached
regarding best ethical and safety practices for digital
monitoring studies.
Psych Res Clin Pract. 2021; 3:57–66; doi: 10.1176/appi.
prcp.20200029
The development of new technologies such as smart-
phones and wearable biosensors has provided unprece-
dented opportunities to study a wide range of mental
health concerns and to improve their understanding, pre-
diction, and prevention. The newfound ability to monitor
people's thoughts, affect, and behavior in real‐time has the
potential to significantly advance the understanding of
potentially harmful behaviors that occur episodically in
natural environments and to develop new just‐in‐time
adaptive interventions (1) to help mitigate them. Perhaps
the most concerning of such clinical high‐risk behaviors
are suicide and its immediate precursors—suicidal
thoughts and behaviors (STBs). Studies using digital
monitoring of those at risk for STBs are increasing
HIGHLIGHTS
� Digital monitoring technologies provide unprecedented
opportunities to study potentially harmful behaviors
such as suicide, violence, and alcohol/substance use in
real‐time, but also introduce myriad ethical and safety
concerns
� We convened a panel of expert scientists, clinicians,
ethicists, legal experts, and those with lived experience
provided input into an iterative, multi‐stage survey and
discussion process
� This study provides guidance for researchers, funding
agencies, and institutional review boards regarding
expert views on current best practices for conducting
digital monitoring studies with those at risk
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exponentially in number in recent years (2). However,
these newly available methods also present unprecedented
scientific, methodological, clinical, ethical, and legal con-
cerns. There has been no consensus among scientists, cli-
nicians, and other stakeholders about best practices for
conducting real‐time monitoring studies of those at risk for
suicide and related behaviors, leaving these parties on their
own to work through these issues and propose solutions.
Prior studies have provided valuable guidance for re-
searchers, funding agencies, and institutional review
boards (IRBs) in planning and carrying out research with
those at risk for suicide (3–5). Digital monitoring methods
present a host of new factors for consideration. Whereas
traditional assessment approaches ask participants to
retrospectively report on the presence, characteristics, and
risk of STBs over a period of weeks or months at a time,
digital monitoring approaches and studies assess such
outcomes at that very moment at which they occur and can
do so repeatedly over periods of minutes, hours, days, and
weeks. Moreover, some digital monitoring apps also allow
the passive collection of data on participants' exact geo-
location (e.g., GPS). This means that digital monitoring
studies often can tell us not only when someone is at risk,
but where someone is at the time of risk. Given these
considerations, funding agencies, IRBs, and researchers
commonly raise important participant safety and privacy
questions to be considered and decided before, during, and
after the conduct of such studies. For instance, what
should researchers do when a participant's response sug-
gests that they are at high or imminent risk for suicide at
that very moment? Is an automated response sufficient to
manage participant risk, or should there be a follow‐up by
phone, text or e‐mail by a member of the research team to
conduct a more thorough risk assessment to ensure
appropriate and timely treatment?
Here we report on a consensus meeting that included
leading scientists, clinicians, ethicists, legal experts, those
with lived experience, and other interested stakeholders
regarding the safe and ethical conduct of digital moni-
toring studies of those at risk for suicide and related be-
haviors. Our goals were to outline areas of consensus to
provide guidance for those using digital monitoring to
study suicidal and related behaviors, and to discover and
discuss areas where there is not yet consensus to point
toward key questions for future research on this topic.
METHODS
Delphi Process
We used a modified Delphi process to obtain expert
opinions about the conduct of digital monitoring studies
with those at risk for suicide and related behaviors. This
approach has been used to obtain expert opinion and
consensus across the medical and social sciences in areas
where none yet exists (6–9). Essential elements of the
Delphi process include: assembling a team of experts
representing a broad range of perspectives, receiving
iterative and anonymous assessments from these experts
to obtain their candid and unbiased input, and group dis-
cussion of key issues facilitated by review of the anony-
mous and aggregated results to allow the group to consider
all perspectives before final assessment of individual ex-
perts’ views on the key issues.
Identification of key issues/questions on this research topic.
The first step in this modified Delphi process was to
generate a list of key issues and questions on this research
topic about which expert consensus was lacking. This was
done via a thorough literature review followed by a series
of discussions between two university‐based clinical sci-
entists (Matthew K. Nock and Evan M. Kleiman) and
National Institute of Mental Health (NIMH)‐based scien-
tists (Jane Pearson, Galia Siegel, and Anna Ordóñez) who
planned and organized the rest of the process. Our
approach was to cast a broad net and to generate issues/
questions at each phase of the research process (outlined
below).
Panel selection. The second step was to generate a
diverse list of experts who could provide guidance on
the range of issues/questions produced. The experts
invited to participate represent the perspectives of those
working in the areas of: science, clinical practice (inpa-
tient/outpatient and child/adolescent/adult), bioethics/
legal/IRB, computer science, statistics, funding agencies
(federal and private), and those with personal/lived
experience with STBs. We invited 23 experts to partic-
ipate in this process. To increase the diversity of per-
spectives included, we also invited four post‐doctoral
and two pre‐doctoral research fellows, each of whom
had multiple years of experience working in this area,
for a total of 29 invitees.
Survey: Round 1. The third step was to develop and send a
19‐item survey to all invited participants. These questions
focused on two time periods: (1) issues to consider before
data collection begins (described in detail in Table 1) and
(2) issues to consider during data collection (described in
detail in Table 2). Consistent with suggested guidelines for
Delphi surveys, (8, 9) this survey was conducted anony-
mously to get participants' unbiased responses to each
question. When possible, questions included response
options that could be easily quantified (e.g., no/yes, check
all that apply) to facilitate efforts to reach a consensus. All
questions also included an open‐ended response option so
that participants could provide more nuanced responses if
the response options did not adequately capture their
perspective. Administration of this survey and all pro-
cedures described here were approved by the Harvard
University IRB. An anonymous link to the survey was
e‐mailed to all 29 invitees. Twenty‐four (82.8%) partici-
pants completed the survey.
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Should any potential participants be excluded due
to elevated risk of suicide? (Select one)
No, we should be collecting data from everyone,
even those at the highest levels of suicide risk
90.5%





Should there be certain conditions participants
must agree to in order to enter/stay in a study,
such as agreeing that they will go to treatment
sessions or call a hotline when at high risk?
(Select one)
No, we can encourage people to do these things
but should not set any such conditions
85.7%
Yes, there should be conditions participants must
agree to enter/stay in the study
14.3%
Informed Consent Should participants be explicitly informed of the
following during informed consent? (Select all
that apply)
Whether responses can trigger follow‐up and/or
intervention actions by the research team and/or
clinicians, which may include breaking of
confidentiality
100%
Information that the participant should not rely on
the study monitoring to keep them safe/alive
100%
Information about who will have access to their
data including third party software developers to
improve their app product
100%
How often researchers will check participants'
responses
95.2%
Circumstances under which the subject's
participation may be terminated by the
investigator without regard to the subject's
consent
95.2%
Who to contact in case of crisis 95.2%
Information that there can be technology failures 95.2%
Information that the participant won't be
automatically hospitalized if their responses
trigger a follow up assessment by the research
team
90.5%
How and what information will be shared with
participants and others if confidentiality is
breached
90.0%
What risk monitoring activities and interventions will
be taking place
76.2%
Issue Question Answer Adults Adolescents
Contact
information
What contact information, including collateral contact
information, should studies be required to collect?




Parent contact information ‐ 90.5%
Participant home address 88.9% 76.2%
Participant email address 83.3% 71.4%
Collateral contact 72.2% 61.9%
Multiple collateral contacts 38.9% 33.3%








Which issues should researchers address BEFORE
data collection begins in a real‐time monitoring
study?
Technology (select all that apply) Figure out what to do when technology fails 100%
Test the alert system 100%
In a standardized manner, go over items of
incidental data collection (medical information,
voice, video) being obtained and the process of
alerting and collecting data
100%
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Consensus meeting. In the fourth step, all invitees were
invited to attend a day‐long, face‐to‐face meeting co‐hosted
by researchers from Harvard University and NIMH.
Twenty‐seven of the 29 invitees attended (93.1%). Each
invitee presented information about their experience and/
or perspectives in this area. We then shared the aggregated
results of the Survey: Round 1 and talked through each
topic assessed in the survey in detail.
Survey: Round 2. In the fifth and final step in this process,
we modified the survey based on the previous round of
responses (e.g., clarifying questions in places where there
was confusion about what was being asked) and on the
discussion at the face‐to‐face meeting. The updated survey
re‐administered the first 13 items of the prior survey
(because we had complete consensus on the final 6 items)
with several modifications. We sent this version of the
survey to the 27 people who participated in the face‐to‐
face meeting (and had the benefit of the extended dis-
cussion about these issues), of whom 21 (77.8%) partici-
pants completed the survey.
Data Analysis
Here we report the results from each of the final questions
asked of this panel of experts. There currently is no agreed
upon standard regarding what constitutes a “consensus”
using the Delphi process (irony noted: no consensus on
consensus). Given the standard convention in the social
and health sciences for considering agreement of 70% or
higher to represent an acceptable level of agreement for
inter‐rater reliability, response rates, validity, and so on, we
considered agreement of 70% or higher to represent
“agreement” (i.e., consensus) and 80% or higher to
represent “strong agreement.”
RESULTS
Issues to Consider Before Data Collection Begins
The panel of experts raised and discussed a range of issues
that encompass decisions about, and interactions with,
potential study participants before data collection begins.
These included issues regarding who to enroll in a study,
under what conditions, what information to include in the
informed consent process, how much contact information
to collect from participants, and what technical and safety
procedures to set in place.
Exclusion of participants. The first question addressed by
the panel was whether any potential participants should be
excluded from real‐time monitoring studies due to
elevated risk of suicide. There was strong agreement that
researchers should aim to collect data from those even at
the highest levels of risk, and thus that potential partici-
pants should not be excluded solely due to high level of
suicide risk. This perspective was endorsed by 19/21 ex-
perts (90.5%). Two people (9.5%) thought that those at
very high risk of STBs should be excluded because they
might be “unable to agree to seek crisis care” or “unable to
respond to ecological momentary assessment prompts.”
Conditions for enrolling in the study. There also was strong
agreement (85.7% of experts) that there should not be any
conditions that participants must agree to in order to
enroll in a real‐time monitoring study, such as agreeing to
be in treatment or call a hotline when at high risk. Experts
also indicated that such contingencies would be difficult to
enforce, would not increase participant safety, and seem
intended to protect the researcher/institution more than
the participant. The 14.3% of experts who indicated that
participants should agree to some conditions to enter or
remain in the study all endorsed that those should include:
(a) agreeing to call a hotline or seek other help when at
high risk, (b) agree to access a clinician when at imminent
risk, and (c) agree to provide data with some frequency. At
least one expert also endorsed each of the following:
agreeing to have a safety plan, providing collateral contact
information, and getting permission from their current
clinician (if they have one) to participate.
Informed consent. The panel reached consensus on 10 el-
ements that should be conveyed to participants during the
consent process (i.e., written in the consent form and
conveyed to the participant verbally when possible). There
was strong consensus for nine of these elements (Table 1),
with consensus, but some divergence of opinion, regarding
whether participants should be informed about what risk
TABLE 1. continued
Issue Question Answer
Safety (select all that apply) Provide the participant with emergency contact
information
100%
Determine what criteria should be used to
delineate specific criteria for triggering further
risk assessment or intervention
100%
Train study staff with risk assessment protocol for
assessing and responding to participant suicidal
ideation and behavior
100%
Solicit feedback from participant about their
desired response from research team for varying
levels of risk
55.0%
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If available technology is not able to alert researchers in real time, how often
should participant data be reviewed by a human on the research team for risk
assessment purposes? (Select one)
More than two times a day 5.3%
Twice every day 21.1%
Once every day 31.6%
Every weekday 31.6%
Less than once a day 10.5%
Determining risk level What key pieces of information should researchers collect to determine a
participant's level of risk? (Select all that apply)
Level of intent to die 94.4%
Presence of suicide plan 94.4%
Access to suicide plan/method 88.9%
Level of desire to die 83.3%
Presence of any suicidal ideation (no/yes) 66.7%
Length of response window When the research team learns that the participant is at "imminent risk," what is the
longest acceptable time window to respond? (Select one)
Within 6 h 22.2%
Within 12 h 50.0%
Within 24 h 22.2%
Within 48 h 0%







What action/intervention should be taken in each case? (Select all
that apply)
Pop up message with suggestions to call a suicide hotline/crisis line 66.7% 66.7%
Pop up message with suggestion to contact participant's supports
such as family
66.7% 50.0%
Pop up message with suggestion to call clinician 61.1% 61.1%
Pop up message with personalized safety plan instructions 61.1% 77.8%
Pop up automated/interactive risk assessment 44.4% 77.8%
Research team contacts participant for risk assessment 11.1% 94.4%
Research team calls 911 to request wellness check 5.5% 50.0%
Issue Question Answer Automated is sufficient
Human outreach
needed
At what level is an automated intervention sufficient and at which level of risk is
human out‐reach required? (Select one option for each row)
Low risk 100% 0%
Moderate risk 80.0% 20.0%
High/imminent risk 20.0% 80.0%
Issue Question Answer Adult Adolescent
Steps for reaching out to
participants
If you believe that human outreach is required, what steps
should be taken if a participant is not reachable by the
research team? (select all that apply)
Formulate a personalized risk plan beforehand that is agreed
upon during consent process
85.0% 80.0%
Notify parent 20.0% 90.0%
Notify collateral contact 65.0% 65.0%
Contact clinician 20.0% 30.0%
Call 911 and send ambulance team to participant 30.0% 30.0%











































monitoring activities and interventions may be taking
place in the study. Some experts believed that efforts to
monitor and intervene during high‐risk situations may be
compromised if participants are made aware of the spe-
cifics of potential monitoring approaches or interventions,
whereas others did not share this concern.
Contact information. There was strong agreement that in-
vestigators conducting digital monitoring studies should
have somemethod of contacting participants in the event of
elevated risk, including: participant phone number, parent
contact information (in the case of child/adolescent partic-
ipants), home address, and email address. There also was
agreement that investigators should obtain contact infor-
mation for at least one collateral person who could help
reach the participant in times of increased risk. There was
not a consensus on a requirement for multiple collaterals,
participants' clinicians' contact information, or having ac-
cess to participants' social media accounts as a means of
communicating. Two notable exceptions to the need for
participant or collateral contact information are studies of
hospital inpatients and those recruited anonymously online.
In the former, hospital staff should be alerted if a participant
reportselevatedrisk. In the latter, referrals tohigher levelsof
care may be made in an automated message/referral.
Technological and safety procedures. There was strong
agreement on seven different technological and safety
procedures that investigators should conduct before
beginning a digital monitoring study in this area (Table 1).
Several experts suggested that investigators should solicit
feedback from participants about their desired response
from the investigative team for various levels of risk;
however, there was not a consensus on this point, as other
experts did not believe that having individual‐level risk
responses is feasible for larger studies.
Issues to Consider During Data Collection
The most challenging aspects of conducting digital moni-
toring research with people at elevated risk for suicide and
related behaviors involve determining when and how to
monitor participant data and manage suicide risk. The
panel of experts spent most of its time discussing issues in
this area, including how frequently to check participant
data, how quickly to respond to those at elevated risk, how
to define and respond to elevated risk, as well as issues of
study monitoring and data security.
Frequency of reviewing participant data. Investigators may
have access to software platforms that allow for contin-
uous, real‐time monitoring of study data. In some in-
stances, real‐time monitoring of data is not possible (e.g., a
survey app does not have the ability to automatically alert
the research team when a participants' response crosses a
specified threshold, or if data are only uploaded when a
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agreed that the research team should have a protocol
specifying the frequency with which a team member
would check the data for high‐risk responses. There was
strong agreement (89.5%) that in such instances data
should be reviewed at least every weekday (Table 2).
There was not consensus regarding how frequently data
should be reviewed within shorter windows.
Determining risk level. Much of the in‐person meeting was
spent discussing how to determine a participant's level of
current risk (e.g., low, moderate, high, and imminent) at a
given assessment point. Although there was no consensus
on how to do this—as is the case with suicide risk assess-
ment more generally (10)—there was strong agreement on
the pieces of information that researchers should collect to
determine risk level: current level of desire to die, level of
intent to die, presence of a suicide plan, and access to the
planned method. Importantly, the group noted that self‐
report of each of these aspects of suicidal thinking/inten-
tion is not necessarily indicative of high probability of
suicidal behavior; determining a given participant's prob-
ability of suicidal behavior at a given point in time is one of
the desired goals of research of this type. In the meantime,
self‐reported level of suicidal thinking/intention is used as
a best estimate of participant level of risk.
Length of response window. Once the research team re-
ceives indication that a participant is at “imminent risk,”
how quickly should they respond? The simple answer is “as
quickly as possible.” However, what if the indication comes
at 2 a.m. or while the team member responsible for
responding is conducting a therapy session or otherwise not
monitoring their phone or computer for messages? There
was strong consensus (94.4%) that the team should respond
within 24 h of receiving an “imminent risk” indication, and
consensus (72.2%) that such a response should be made
within 12 h. For instance, a teammay not have the resources
(e.g., person‐power) to monitor responses overnight (e.g., 9
p.m.–9 a.m.), but in such a case should respond no longer
than 12 h after the imminent risk indication was received.
Potential interventions. The majority of experts (>61.1%)
believed that for those currently at low/moderate risk, an
automatedmessage suggesting that the participant contact a
crisis line, support person, or clinician is a sufficient
response by the research team. For those at high risk, there
was consensus that participants should receive a personal-
ized safety plan and/or an automated additional risk
assessment (77.8%), and some experts suggested that best
practice should be to always have a safety plan (and asso-
ciated call numbers) readily available to participants within
the survey app. There was strong consensus that in cases of
high risk the research team should reach out to the partic-
ipant directly to conduct a risk assessment (94.4%). There
was not consensus about the need to call 911 to request a
wellness check, with 50% of experts endorsing such an ac-
tion. Some experts suggested this “should be the last
possible option” and noted potential negative consequences
to doing so in cases of working with potentially vulnerable
participants, such as racial/ethnic minority participants,
who experience significantly higher rates of physical force
and death in police‐initiated contacts (11, 12).
The group also discussed the extent to which an auto-
mated intervention (e.g., pop‐up with safety plan or one‐
touch call to clinician or hotline) versus human outreach
(e.g., call, text, or email from member of the research team)
TABLE 3. Main points of consensus in digital monitoring
studies of those at risk for suicide and related behaviors
Researchers conducting real‐time monitoring studies
of those at risk for suicide and related behaviors
should strive to:
1. Not exclude participants soley on the basis of
elevated clinical severity or suicide risk.
2. Not exclude or remove participants who are not
willing or able to meet pre‐specified conditions for
participant or help‐seeking (e.g., remaining in
treatment or calling a hotline when at high risk).
3. Provide participants with explicit information
about key elements of study procedures during
the informed consent process.
4. Collect and retain (during the real‐time moni-
toring period) contact information (phone, email,
and home address) from both the participant and
at least one collateral to facilitate contacting par-
ticipants during periods of perceived elevated
risk.
5. Address key aspects of technology use and
participant safety before proceeding with data
collection.
6. Review participant survey responses at least once
every weekday.
7. Respond to those determined to be at “imminent
risk” for suicide within 12 h of learning of this
risk.
8. Collect data about suicidal desire, intent, plan to
determine participants' level of risk.
9. Respond to participants determined to be at high
or “imminent” risk for suicide with automated
risk assessments, safety plans, and human
outreach (depending on risk and type of study) as
soon as possible.
10. Store data in de‐identified form, in secure servers,
and in compliance with HIPAA guidelines. In
cases in which data safety and monitoring boards
are used they should include at least one person
with expertise managing suicide risk.
NOCK ET AL.
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should be used. There was strong consensus that auto-
mated interventions are sufficient for low risk and mod-
erate risk situations, but that human outreach is preferred
for high‐risk situations and in studies of minors. Experts
noted that automated outreach is sufficient in studies
where participation is anonymous. There was strong
consensus that researchers should formulate a personal-
ized risk plan with each participant before the monitoring
portion of the study begins to guide procedures for
responding to instances in which participants do not
respond to initial calls, texts, or emails from the research
team (Table 2). There also was strong consensus that in
studies involving youth, a parent should be contacted in
instances of non‐response by high‐risk adolescents.
Participant removal. An important question in the current
context is whether participants should be removed
(temporarily or permanently) from the study by the
research team (vs. an individual participant's wish to dis-
continue), due to elevated risk of suicide or clinical
severity or worsening. There was strong consensus among
experts that no participants should be removed from real‐
time monitoring studies—as it is important to understand
and be able to predict harmful behavior among those at all
levels of risk, particularly those at highest risk.
Data safety and monitoring. Data and Safety Monitoring
Boards (DSMBs) and Independent Safety Monitors (ISMs)
often are required for NIMH‐supported grants.nih.gov/
grants/glossary.htm" title¼"http://grants.nih.gov/grants/
glossary.htm">clinical trials “to assure the safety of research
participants, regulatory compliance, and the data integrity,”
(3, 13) but could be used in any study. One of their main
functions is to review adverse events. There was not
consensus on the requirement for DSMBs or ISMs in the
case of real‐time monitoring assessment studies. Approxi-
mately one‐third (31.6%) of experts indicated that they are
not needed for such studies, one‐half (47.4%) indicated they
are needed but only for studies where participants are
recruited because they are at high risk, and a smaller per-
centage (21.1%) indicated they should be required of all such
studies. For those indicating that such studies should have a
DSMB/ISM, there was strong consensus that there should
be a requirement that suchoversight is providedby someone
with expertise managing suicide risk (Table 2).
Data security. Therewas strong consensus that researchers
conducting such research use secure web‐based platforms
and de‐identified data storage, and consensus that HIPAA
compliant platforms also should be used in such research.
DISCUSSION
Digital monitoring technologies provide unprecedented
opportunities to advance the understanding of suicide and
related behaviors. However, there are not yet accepted
guidelines regarding ethical and safety practices for con-
ducting research studies in this area. We convened a panel
of experts to attempt to reach consensus about key con-
siderations in this area based on currently available data and
perceived best practices. This panel of experts reached
consensus on a number of key issues regarding ethical and
safety practices for conducting digital monitoring studies
with those at high clinical risk (Table 3). Many of these
aspirations reflect the need to expand study inclusion to
participants with significant suicide risk, since historically
they have been typically excluded from research. In many
cases these aspirations also reflect the need for significant
resources to enable researchers to conduct intensive lon-
gitudinal monitoring and real‐time risk management and
intervention, which is not always possible. This consensus
statement can help to guide researchers, funding agencies,
and IRBs involved in the planning, conduct, and oversight of
research studies in this area. Notably, the panel of experts
discussed and endorsed the fact that these views are based
on currently available data and thinking, and that these
views may evolve over time as additional data and consid-
erations become available—highlighting the need to revisit
these ethical and safety considerations iteratively over time.
There also were several areas in which the panel did
not reach consensus. These included: (a) determination of
what constitutes low, moderate, high, and imminent risk
for suicide and related behaviors; (b) determination of the
most effective intervention for each risk level; and (c) the
requirements for using DSMBs and ISMs for monitoring
studies of this type. Reaching consensus on the first two
areas requires additional empirical data. Historically, de-
terminations about level of risk for suicide and related
behaviors and the most appropriate response (e.g., hospi-
talization) have been made primarily based on clinical
judgment and decision‐making. Recent advances in elec-
tronic record‐keeping and machine learning have signifi-
cantly enhanced the ability to predict suicidal and related
behaviors, (14–16) and similar innovations are needed in
studies of real‐time digital monitoring. Still absent from all
such studies are data on the most effective intervention for
a particular person at a particular time point—a long‐
standing question in mental health research and practice
(17). Efforts to address questions such as this are currently
underway (18, 19) and hopefully will provide guidance that
can be used to update the current consensus at that time.
This panel of experts considered, but did not suffi-
ciently discuss, several related topics that require further
attention. These include further incorporation of research
participants' perspectives; consideration of issues unique
to children and adolescents; issues unique to other be-
haviors such as substance use (e.g., if/how to intervene if
the research team believes a person may operate an
automobile while intoxicated?); and issues unique to other
digital platforms such as social media apps. The current
effort represents a key step toward providing consensus
guidance on safety and ethical practices for conducting
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digital monitoring studies with those at high clinical risk.
Additional, iterative efforts are needed to provide ongoing
guidance on these important topics.
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